Papers - Yamagami, Wataru

Advancing Precision Oncology: Whole-Exome Sequencing in Endometrial Cancer Liquid-Based Cytology

Takamatsu R, Nakamura K, Chiyoda T, Tsuji K, Kawano R, Yoshimi N, Yamagami W, Nishihara H

Arch Pathol Lab Med 149 ( 6 ) 561 - 567 2025.06

Research paper (scientific journal), Joint Work

Prognostic impact of peritoneal cytology on treating endometrial cancer using data from the Japan Society of Obstetrics and Gynecology cancer registry

Sakai K, Yamagami W, Takahashi F, Tokunaga H, Yamamoto E, Yokoyama Y, Yoshino K, Kawana K, Nagase S

J Gynecol Oncol 36 ( 3 ) e41 - e41  2025.05

Research paper (scientific journal), Joint Work

CXCL9 and CXCL13 shape endometrial cancer immune-activated microenvironment via tertiary lymphoid structure formation

Nagase Y, Kodama M, Aimono E, Nakamura K, Takamatsu R, Abe K, Yoshimura T, Chiyoda T, Yamagami W, Nishihara H

Cancer Sci 116 ( 5 ) 1193 - 1202 2025.05

Research paper (scientific journal), Joint Work

mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer

Tamura T, Nagai S, Masuda K, Imaeda K, Sugihara E, Yamasaki J, Kawaida M, Otsuki Y, Suina K, Nobusue H, Akahane T, Chiyoda T, Kisu I, Kobayashi Y, Banno K, Sakurada K, Okita H, Yamaguchi R, Ahmed AA, Yamagami W, Saya H, Aoki D, Nagano O

Cancer Lett 616   217565 - 217565 2025.04

Research paper (scientific journal), Single Work

難治性のほてり・発汗に対して補腎剤が著効した3症例

横田めぐみ，椎名美季，大野あゆみ，谷本慧子，堀場裕子，山上 亘

産婦人科漢方研究のあゆみ 40   58 - 62 2025.04

Research paper (scientific journal), Joint Work

めまいを訴える更年期女性への漢方処方と効果

椎名美季，横田めぐみ，大野あゆみ，谷本慧子，堀場裕子，山上 亘

産婦人科漢方研究のあゆみ 40   26 - 30 2025.04

Research paper (scientific journal), Joint Work

横紋筋融解症を発症し早産に至った筋強直性ジストロフィー合併妊娠の1例

山田 郁，大谷利光，緒方泰彦，石川直嗣，梶川かおる，秋田啓介，玉井順子，田中雄也，春日義史，池ノ上 学，山上 亘，田中 守

東京産科婦人科学会会誌 74 ( 2 ) 367 - 370 2025.04

Joint Work, Accepted

Immunotherapy for endometrial cancer

Wada M, Yamagami W

Int J Clin Oncol 30 ( 3 ) 449 - 456 2025.03

Research paper (scientific journal)

子宮内膜異型増殖症に対する鏡視下子宮全摘出術前における、子宮内膜全面掻爬術の有用性に関する検討

坂巻智美，吉村拓馬，落合大輔，地阪光代，平田 桃，高橋美央，坂井健良，和田美智子，千代田達幸，山上 亘，田中 守

東京産科婦人科学会会誌 74 ( 1 ) 8 - 12 2025.01

Research paper (scientific journal), Joint Work, Accepted

Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series

Adachi T., Matsui T., Okata-Karigane U., Takahashi C., Tahara U., Hyodo M., Miyagawa A., Kobayashi K., Nakamura Y., Funakoshi T., Nishio H., Yamagami W., Takahashi H.

Journal of Dermatology 52 ( 1 ) 132 - 137 2025.01

Research paper (scientific journal), Joint Work,  ISSN  03852407

　View Summary

Immune checkpoint inhibitors (ICIs), such as pembrolizumab (PEM), are widely recognized for their antitumor efficacy, but they can also lead to various cutaneous adverse events (CAEs). While most CAEs can be managed with topical corticosteroids, severe cases may necessitate halting immunotherapy. The incidence of severe CAEs is notably higher in combination therapies involving ICIs than in monotherapies, emphasizing the need for stringent, long-term management strategies. This includes potential modifications or discontinuations of the combination therapy. PEM, when added to the conventional paclitaxel + cisplatin (or carboplatin) ± bevacizumab regimen, has shown significant improvements in overall and progression-free survival for patients with Stage IVB metastatic or locally uncontrolled recurrent cervical cancer. This case series retrospectively examined the incidence and management of CAEs in 19 female patients treated with this combination therapy between October 2022 and May 2023. Four patients exhibiting CTCAE grade 3 were identified. The four cases of severe CAEs involved erythema multiforme after the initial course of PEM combination chemotherapy. Notably, three patients experienced immediate hypersensitivity reactions, including anaphylaxis, during subsequent treatments. This observation underscores the necessity for rigorous dermatological monitoring of patients undergoing PEM combination chemotherapy. Such vigilance is crucial for early detection of adverse reactions and timely adjustment of treatment regimens, thereby enhancing patient safety.

• Access to Document (DOI)

Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis

Takahashi M, Nakamura K, Chiyoda T, Okada C, Nohara S, Takamatsu R, Yanazume S, Kobayashi H, Nishihara H, Yamagami W

Cancer Med 14 ( 2 ) e70601 - e70601 2025.01

Research paper (scientific journal), Joint Work

Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis

Konno Y, Mayama M, Takehara K, Yokoyama Y, Suzuki J, Susumu N, Harano K, Nakagawa S, Nakanishi T, Yamagami W, Yoshihara K, Nomura H, Okamoto A, Aoki D, Watari H

J Gynecol Oncol 36 ( 1 ) e3 - e3 2025.01

Research paper (scientific journal), Joint Work

Safe Implementation of Robotic Surgery for Gynecologic Diseases at a Tertiary Center: Retrospective Analysis of 149 Cases and Review of the Literature

Yoshimura T, Nishio H, Sakai K, Nogami Y, Hayashi S, Yamagami W

Gynecol Minim Invasive Ther 14 ( 1 ) 33 - 39 2024.12

Research paper (scientific journal)

The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.

Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T

Cancer discovery 14 ( 11 ) 2243 - 2261 2024.11

ISSN  2159-8274

• Access to Document (DOI)

術中迅速病理診断で類内膜癌G1/G2,筋層浸潤1/2未満の子宮体癌に対して骨盤リンパ節郭清は必要か?

吉村拓馬，坂井健良，落合大輔，坂巻智美，地阪光代，高橋美央，吉浜智子，千代田達幸，田中 守，山上 亘

関東連合産科婦人科学会誌 61 ( 4 ) 479 - 484 2024.11

Research paper (scientific journal), Joint Work

A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese. Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial)

Sakai K, Yamagami W, Sato Y, Susumu N, Yokoyama Y, Takehara K, Mandai M, Okamoto A

J Gynecol Oncol 35 ( 6 ) e106 - e106 2024.11

Research paper (scientific journal), Joint Work

子宮体癌における術後補助化学中に壊死性筋膜炎が疑われた1例

真鍋悠歌，横田めぐみ，高畑海音子，和田美智子，山上 亘，田中 守

東京産科婦人科学会会誌 73 ( 4 ) 811 - 817 2024.10

Research paper (scientific journal), Joint Work, Accepted

子宮頸管妊娠に対しメトトレキサート（MTX）と子宮動脈塞栓症（UAE）を併用し保存的治療を行った2例

白石 慧，上條慎太郎，佐久間萌子，大岡令奈，松沢優一，内田志穂，祝井麻希，内田明花，山田満稔，山上 亘，田中 守

東京産科婦人科学会会誌 73 ( 4 ) 848 - 853 2024.10

Research paper (scientific journal), Joint Work, Accepted

Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan.

Machida H, Matsuo K, Higashi T, Aoki D, Enomoto T, Okamoto A, Katabuchi H, Nagase S, Mandai M, Yaegashi N, Yamagami W, Mikami M

Journal of gynecologic oncology 35 ( 5 ) e61 2024.09

Research paper (scientific journal), Joint Work,  ISSN  2005-0380

• Access to Document (DOI)

Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks

Onji H., Tate S., Sakaue T., Fujiwara K., Nakano S., Kawaida M., Onishi N., Matsumoto T., Yamagami W., Sugiyama T., Higashiyama S., Pommier Y., Kobayashi Y., Murai J.

Oncogene 43 ( 32 ) 2475 - 2489 2024.08

ISSN  09509232

　View Summary

The preferential response to PARP inhibitors (PARPis) in BRCA-deficient and Schlafen 11 (SLFN11)-expressing ovarian cancers has been documented, yet the underlying molecular mechanisms remain unclear. As the accumulation of single-strand DNA (ssDNA) gaps behind replication forks is key for the lethality effect of PARPis, we investigated the combined effects of SLFN11 expression and BRCA deficiency on PARPi sensitivity and ssDNA gap formation in human cancer cells. PARPis increased chromatin-bound RPA2 and ssDNA gaps in SLFN11-expressing cells and even more in cells with BRCA1 or BRCA2 deficiency. SLFN11 was co-localized with chromatin-bound RPA2 under PARPis treatment, with enhanced recruitment in BRCA2-deficient cells. Notably, the chromatin-bound SLFN11 under PARPis did not block replication, contrary to its function under replication stress. SLFN11 recruitment was attenuated by the inactivation of MRE11. Hence, under PARPi treatment, MRE11 expression and BRCA deficiency lead to ssDNA gaps behind replication forks, where SLFN11 binds and increases their accumulation. As ovarian cancer patients who responded (progression-free survival >2 years) to olaparib maintenance therapy had a significantly higher SLFN11-positivity than short-responders (<6 months), our findings provide a mechanistic understanding of the favorable responses to PARPis in SLFN11-expressing and BRCA-deficient tumors. It highlight the clinical implications of SLFN11. (Figure presented.)

• Access to Document (DOI)